Phio Pharmaceuticals Corp.
New Form D on file · 2025-11-12 · the record
Phio Pharmaceuticals Corp. filed a Form D with the Securities and Exchange Commission on 2025-11-12.
Phio Pharmaceuticals Corp. filed a Form D notice of an exempt securities offering with the SEC on November 12, 2025. The filing reports $1.42M sold. Its industry group is Biotechnology. It names Robert Bitterman (Director, Executive Officer), Patricia Bradford (Director), Jonathan Freeman (Director) (SEC Form D, November 12, 2025).
Is this your company?
Sell to companies like Phio Pharmaceuticals Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-11-12 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Phio Pharmaceuticals Corp.
Free to see. No signup.
More on the people and the money behind Phio Pharmaceuticals Corp., from the filings we hold.
H.C. Wainwright & Co, LLC received sales compensation on this raise and on 19 other raises we hold, nearest in date first:
Biotechnology raises by companies based in Pennsylvania, filed within 90 days of this one, largest first.
Get an email when Phio Pharmaceuticals Corp. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Phio Pharmaceuticals Corp. raises, hires or launches. No email unless you switch it on.
Watch Phio Pharmaceuticals Corp. →Get the full cited report on Phio Pharmaceuticals Corp.
What the filing shows about Phio Pharmaceuticals Corp.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Phio Pharmaceuticals Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Phio Pharmaceuticals Corp.'s address as 411 Swedeland Road, Suite 23-1080, King Of Prussia, PA 19406.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Phio Pharmaceuticals Corp. See pricing
Phio Pharmaceuticals Corp. is a registered filer with the SEC (CIK 1533040) and has filed since 2022-11-23. 12 filings are on record, the latest on 2025-11-12.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Phio Pharmaceuticals Corp.'s Form D of 2025-11-12 names Robert Bitterman, Patricia Bradford, Jonathan Freeman and 3 more as its officers, directors or promoters.
Its new offerings report $10.04M sold across 12 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 764 filings in Biotechnology, totalled by week. The dot is this raise, $1.42M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Robert Bitterman is named as Director and Executive Officer on the Form D that Phio Pharmaceuticals Corp. filed with the SEC on 12 November 2025, one of 6 people that filing names.
Patricia Bradford is named as Director on the Form D that Phio Pharmaceuticals Corp. filed with the SEC on 12 November 2025, one of 6 people that filing names.
Jonathan Freeman is named as Director on the Form D that Phio Pharmaceuticals Corp. filed with the SEC on 12 November 2025, one of 6 people that filing names.
Curtis Lockshin, Ph.D. is named as Director on the Form D that Phio Pharmaceuticals Corp. filed with the SEC on 12 November 2025, one of 6 people that filing names.
David Deming is named as Director on the Form D that Phio Pharmaceuticals Corp. filed with the SEC on 12 November 2025, one of 6 people that filing names.
Lisa Carson is named as Executive Officer on the Form D that Phio Pharmaceuticals Corp. filed with the SEC on 12 November 2025, one of 6 people that filing names.
6 people named on the filing — 2 holding an executive role and 4 as directors only.
Named as of the 2025-11-12 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Phio Pharmaceuticals Corp.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Phio Pharmaceuticals Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Phio Pharmaceuticals Corp. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Phio Pharmaceuticals Corp.You get an alert in MentionFox the next time this company shows up.
If you're behind Phio Pharmaceuticals Corp.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Phio Pharmaceuticals Corp.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Philadelphia
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.

https://mentionfox.com/funding/phio-pharmaceuticals-corp-form-d-25000001